News
QNRX
0.7139
-3.66%
-0.0271
Weekly Report: what happened at QNRX last week (0408-0412)?
Weekly Report · 21h ago
Weekly Report: what happened at QNRX last week (0401-0405)?
Weekly Report · 04/08 12:23
Weekly Report: what happened at QNRX last week (0325-0329)?
Weekly Report · 04/01 12:20
Weekly Report: what happened at QNRX last week (0318-0322)?
Weekly Report · 03/25 12:23
Weekly Report: what happened at QNRX last week (0311-0315)?
Weekly Report · 03/18 12:21
Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know
Maxim Group has maintained its Buy rating of Quoin Pharmaceuticals and lower its price target from $15.00 to $4.00. The company is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Shares of quoin pharmaceuticals are trading up 2.0% over the last 24 hours.
Benzinga · 03/15 17:00
Quoin Pharmaceuticals Price Target Cut to $4.00/Share From $15.00 by Maxim Group
Dow Jones · 03/15 15:25
Quoin Pharmaceuticals Is Maintained at Buy by Maxim Group
Dow Jones · 03/15 15:25
Maxim Group Maintains Buy on Quoin Pharmaceuticals, Lowers Price Target to $4
Benzinga · 03/15 15:15
Quoin Pharmaceuticals GAAP EPS of -$2.08
Seeking Alpha · 03/13 20:21
Quoin Pharmaceuticals: Q4 Earnings Insights
Quoin Pharmaceuticals reported its Q4 earnings on March 13. The company beat estimates by 10.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.77 and the share price fell 8.0% the next day.
Benzinga · 03/13 20:15
Quoin Pharmaceuticals Q4 2023 GAAP EPS $(2.08) Beats $(2.31) Estimate
Benzinga · 03/13 20:13
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Barchart · 03/13 15:05
Earnings Scheduled For March 13, 2024
Sangamo Therapeutics is expected to report earnings for its fourth quarter. Dollar Tree is estimated to report quarterly earnings at $2.65 per share on revenue of $8.67 billion. Other companies reporting before the bell and after the bell include i-80 Gold and Optical Cable.
Benzinga · 03/13 10:15
Preview: Quoin Pharmaceuticals's Earnings
Quoin Pharmaceuticals is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Analysts estimate the company will report an earnings per share of $-2.31. Last quarter the company beat EPS by $0.77, but shares are down 81.67% over the last 52 weeks.
Benzinga · 03/12 17:01
Weekly Report: what happened at QNRX last week (0304-0308)?
Weekly Report · 03/11 12:16
Samsara, DocuSign, Gap among premarket gainers' pack
Seeking Alpha · 03/08 13:30
12 Health Care Stocks Moving In Friday's Pre-Market Session
Ainos (NASDAQ:AIMD) shares increased by 144.6% to $2.74 during Friday's pre-market session. The company's market cap stands at $12.8 million. Psyence Biomedical stock moved upwards by 107.87% during the session. Mira Pharmaceuticals stock increased by 77.91% in the same session.
Benzinga · 03/08 13:09
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Ainos (NASDAQ:AIMD) stock is rocketing more than 167% higher alongside heavy pre-market trading this morning. Mira Pharmaceuticals shares are soaring over 62% following an update on its clinical trials. Earnings reports, clinical trial updates and more are driving the biggest pre- market stock movers for Friday morning.
Investorplace · 03/08 12:36
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
U.S. Stocks traded lower on Tuesday, with the Dow Jones falling around 350 points. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85%. Energy shares rose by 1.3% on Tuesday; information technology shares fell by 2.2%. Asian markets closed mostly lower while European shares closed mixed. In commodity news, oil traded down 1% to $77.95 while gold traded up 1%.
Benzinga · 03/05 19:11
More
Webull provides a variety of real-time QNRX stock news. You can receive the latest news about Quoin Pharmaceuticals Ltd through multiple platforms. This information may help you make smarter investment decisions.
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.